Eli Lilly has recently announced several developments, including positive Phase 2 results for their siRNA therapy lepodisiran and the expansion of their digital healthcare platform, LillyDirect ...

Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...

The results could be harmful to them in more ways than one. Despite this issue, Eli Lilly remains a top stock to buy. As everyone who follows equity markets knows, stocks are feeling the heat from ...

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity ...

Following a three-day selloff amid market turmoil attributed to the Trump administration’s sweeping tariffs announced last week, Eli Lilly (NYSE:LLY) shares traded higher in the premarket on ...

April 8 - Eli Lilly (NYSE:LLY) shares rose about 5% Tuesday morning after Goldman Sachs (NYSE:GS) upgraded the pharmaceutical giant to Buy from Neutral, citing confidence in its leadership in the ...

Drug manufacturer Eli Lilly's weight loss pill has completed late-stage trials for people with type 2 diabetes. The pill could offer an alternative to injectables. 90-day clock expires on ...

Eli Lilly LLY underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a ...

Eli Tomac is back on his bike, practicing for a return to the SuperMotocross League in May. “Back at it,” Tomac posted on social media. “Goal as of now is [Pro Motocross] Round 1, would love to sneak ...

You can reach Elaine on Signal at elaineywchen.70. A daily pill from Eli Lilly helped patients with type 2 diabetes improve their blood sugar and shed weight, the company said Thursday ...

Eli Lilly and Company is the world's most valuable Pharma thanks to tirzepatide, a groundbreaking GLP-1 weight-loss and Type 2 Diabetes drug, marketed and sold as Zepbound / Mounjaro. Hims & Hers ...

Eli Lilly helps struggling Sangamo with $1.4B gene therapy deal By Darren Incorvaia Apr 3, 2025 6:00pm Sangamo Therapeutics Eli Lilly Licensing deals Cell & Gene Therapy ...